Arsenic Trioxide Injection
Brand names: Arsenic Trioxide
Category: Oncology
FDA status: To Be Discontinued · Last FDA update: Sep 21, 2026 · First posted: Feb 24, 2026 · 2 manufacturers, 2 listed presentations
As of Sep 21, 2026, the FDA lists Arsenic Trioxide Injection as being discontinued. Of 2 manufacturer presentations, 2 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 63323-637-10) NDC 63323-637-10 |
Fresenius Kabi USA, LLC | Not specified | Discontinuation of the manufacture of the drug |
| Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 50742-438-10) NDC 50742-438-10 |
Ingenus Pharmaceuticals LLC | Not specified | A business decision was made to discontinue manufacture of the drug. |
Related medications in shortage
Other Oncology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Arsenic Trioxide Injection (FDA data as of Sep 21, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Arsenic Trioxide Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/arsenic-trioxide-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).